Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 AlteredExpression group BEFREE We used conditional transgenic mice induced to overexpress GLI1 in the mammary epithelium either alone or in combination with deletion of one Trp53 allele to address the role of elevated GLI1 expression in breast tumour initiation and progression. 31219615 2020
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 AlteredExpression group BEFREE PSL@RES induced apoptosis in breast tumor by upregulation of p53 expression. 31746932 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.500 AlteredExpression group BEFREE In breast tumors, PD-L1 expression levels are the highest in estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-negative (triple-negative) cancers. 31796994 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.500 Biomarker group BEFREE US specificity was lower in grade III (P < .001), estrogen receptor (ER)-negative (P < .001), progesterone receptor (PR)-negative (P = .004), HER2-positive (P = .015), triple-negative (P = .001), and larger breast tumors (P < .001). 31562691 2020
Entrez Id: 79728
Gene Symbol: PALB2
PALB2
0.500 GeneticVariation group BEFREE Compared with non-carriers, PALB2 pathogenic mutation carriers developed breast cancer at a younger age (47.52 years vs. 51.35 years, p = 0.016) and were more likely to have triple-negative (24.1% vs. 13.4%, p = 0.022) or HER2 negative (87.0% vs. 74.2%, p = 0.031) breast cancer and large breast tumors (> 2 cm) at diagnosis (72.2% vs. 57.0%, p = 0.024). 31768816 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.500 Biomarker group BEFREE Small molecule inhibitors (TKIs) of HER2 have demonstrated clinical benefit in HER2-positive breast tumors. 31765734 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.500 Biomarker group BEFREE Women with HER2-positive breast tumors measuring ≥2 cm (median=5 cm) were randomized in a 1:2 ratio to 12 vs. 24 weeks of lapatinib and trastuzumab. 31662331 2020
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.500 Biomarker group BEFREE US specificity was lower in grade III (P < .001), estrogen receptor (ER)-negative (P < .001), progesterone receptor (PR)-negative (P = .004), HER2-positive (P = .015), triple-negative (P = .001), and larger breast tumors (P < .001). 31562691 2020
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.500 GeneticVariation group BEFREE Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors. 31139940 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.500 Biomarker group BEFREE Acquired resistance to HER2-targeted therapies occurs frequently in HER2+ breast tumors and new strategies for overcoming resistance are needed. 31690671 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.500 Biomarker group BEFREE Food and Drug Administration (FDA)-approved in February 2019, SQ trastuzumab, a monoclonal antibody that binds to human epidermal growth factor receptor 2 (HER2) protein in combination with hyaluronidase, offers an alternative dosage form for patients with breast tumors overexpressing HER2. 31595774 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.500 GeneticVariation group BEFREE Compared with non-carriers, PALB2 pathogenic mutation carriers developed breast cancer at a younger age (47.52 years vs. 51.35 years, p = 0.016) and were more likely to have triple-negative (24.1% vs. 13.4%, p = 0.022) or HER2 negative (87.0% vs. 74.2%, p = 0.031) breast cancer and large breast tumors (> 2 cm) at diagnosis (72.2% vs. 57.0%, p = 0.024). 31768816 2020
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.400 Biomarker group BEFREE US specificity was lower in grade III (P < .001), estrogen receptor (ER)-negative (P < .001), progesterone receptor (PR)-negative (P = .004), HER2-positive (P = .015), triple-negative (P = .001), and larger breast tumors (P < .001). 31562691 2020
Entrez Id: 7124
Gene Symbol: TNF
TNF
0.400 Biomarker group BEFREE Advanced-stage breast tumors have a high concentration of tumor necrosis factor-α (TNFα) throughout the tumor/stroma milieu, prompting sustained release of diverse chemokines (i.e. 31659097 2020
Entrez Id: 6774
Gene Symbol: STAT3
STAT3
0.400 Biomarker group BEFREE Ablating T cell Stat3 or treatment with an FAO inhibitor in obese mice spontaneously developing breast tumor reduces FAO, increases glycolysis and CD8<sup>+</sup> T effector cell functions, leading to inhibition of breast tumor development. 31761565 2020
Entrez Id: 207
Gene Symbol: AKT1
AKT1
0.400 GeneticVariation group BEFREE Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors. 31139940 2020
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.100 Biomarker group BEFREE Evaluation of plasma and tissue expression levels of Endothelins (ET-1, Big ET-1) and VEGF in lobular neoplasia of the breast. 31786855 2020
Entrez Id: 960
Gene Symbol: CD44
CD44
0.100 Biomarker group BEFREE CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors <i>in Vivo</i>. 31532629 2020
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 GeneticVariation group BEFREE Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors. 31139940 2020
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
0.100 GeneticVariation group BEFREE Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors. 31139940 2020
Entrez Id: 5291
Gene Symbol: PIK3CB
PIK3CB
0.100 GeneticVariation group BEFREE Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors. 31139940 2020
Entrez Id: 3159
Gene Symbol: HMGA1
HMGA1
0.060 Biomarker group BEFREE HMGA1 IRS was generated from breast tumors in Korean women as the product of staining intensity (weak = 1, moderate = 2, strong = 3) and percent positive cells (< 5% = 0, 5-30% = 1, 30-60% = 2, > 60% = 3), and stratified into three groups: low (< 3), intermediate (3-6), high (> 6). 31531802 2020
Entrez Id: 3308
Gene Symbol: HSPA4
HSPA4
0.060 AlteredExpression group BEFREE We screened CEA, CCBN1, c-Myc, p53, Ki-67, Nm23, PRDX6, eIF5A, PARK7, GLIO-1, Hsp27 and Hsp70 proteins, previously detected as up-regulated in breast tumors of Mexican patients. 31839604 2020
Entrez Id: 8061
Gene Symbol: FOSL1
FOSL1
0.060 GeneticVariation group BEFREE Association of FOSL1 copy number alteration and triple negative breast tumors. 30816904 2020
Entrez Id: 7068
Gene Symbol: THRB
THRB
0.050 Biomarker group BEFREE Since the thyroid hormone receptor β (TRβ) appears to suppress breast tumor growth and metastasis, we have analyzed the possibility that TRβ could affect the CSC population using MCF-7 cells grown under adherent conditions or as mammospheres, as well as inoculation into immunodeficient mice. 31760908 2020